Assessing Whether Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Is Over- Or Undervalued
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.59, with 14.5 million shares of worth about $8.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.73% during that period and on November 14, 2024 the price saw […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) – Suitable For Long Term Buy?
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling […]
